Clinical Trial: Effects of AI-generated misinformation about the effectiveness of dietary supplements against hypertension on health beliefs and behavioral intentions among the Japanese general public: a randomized controlled trial (Japan)

Tokyo, May 10 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000061491) titled 'Effects of AI-generated misinformation about the effectiveness of dietary supplements against hypertension on health beliefs and behavioral intentions' on May 8.

Study Type: Interventional

Study Design: Basic Design - Parallel Randomization - Randomized Blinding - Single blind -participants are blinded Control - Active

Primary Sponsor: Institute - The University of Tokyo

Condition: Condition - Exposure to dietary supplement misinformation related to hypertension Classification by malignancy - Others Genomic information - NO

Objective: Narrative objectives1 - This study aims to examine whether exposure to AI-generated misinformation about the effectiveness of dietary supplements against hypertension affects beliefs about the effectiveness of dietary supplements against hypertension, purchase or intake intentions, information-sharing intentions, and intentions to consult health professionals among the Japanese general public. Basic objectives2 - Others

Intervention: Interventions/Control_1 - Participants in the intervention group view AI generated misinformation claiming that one of four dietary supplements.euglena, turmeric, probiotics, or oyster extract is effective for lowering blood pressure, maintaining heart and vascular health, or preventing hypertension. The message is viewed once during the web-based survey and is displayed for approximately 20 seconds. After viewing the message, participants answer questions on health beliefs and behavioral intentions. At the end of the survey, accurate information and cautionary statements are provided to prevent misunderstanding. Interventions/Control_2 - Participants in the control group view AI generated accurate information stating that there is insufficient scientific evidence that one of the same four dietary supplements, euglena, turmeric, probiotics, or oyster extract is effective for treating hypertension, lowering blood pressure, or preventing hypertension. The message is viewed once during the web-based survey and is displayed for approximately 20 seconds. After viewing the message, participants answer questions on health beliefs and behavioral intentions.

Eligibility: Age-lower limit - 18 years-old

Gender - Male and Female Key inclusion criteria - Individuals aged 18 to 64 years Registered panel members of a Japanese survey company who are able to complete an online survey Individuals who have experience using generative AI Individuals who provide informed consent online Key exclusion criteria - Individuals who are not aware of dietary supplements Individuals who have no experience using generative AI Health care professionals, including physicians, nurses, pharmacists, registered dietitians, and dietitians Individuals working in the AI field, including AI researchers or developers Individuals with a personal or household history of hypertension Individuals currently receiving dietary therapy under the guidance of health professionals Individuals who fail the attention-check question Target Size - 800

Recruitment Status: Recruitment status - No longer recruiting Date of protocol fixation - 2026 Year 03 Month 04 Day Date of IRB - 2026 Year 03 Month 03 Day Anticipated trial start date - 2026 Year 03 Month 10 Day Last follow-up date - 2026 Year 04 Month 20 Day

To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000070362

Disclaimer: Curated by HT Syndication.